Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936680 | 0.94 | PPARD (0.39) | PPARDMMP1MMP2FNTAFNTB | |
| SCHEMBL12446831 | 0.81 | HSD11B1 (0.40) | PPARDHSD11B1MMP1MMP2GAA | |
| SCHEMBL4163826 | 0.81 | PPARD (0.39) | PPARDMMP1MMP2FNTAFNTB | |
| SCHEMBL4995518 | 0.79 | MMP1 (0.40) | PPARDMMP1MMP2HPGDMETAP1 | |
| SCHEMBL3939836 | 0.77 | PPARD (0.41) | PPARDMMP1MMP2FNTAFNTB | |
| SCHEMBL4943147 | 0.76 | ALDH1A1 (0.37) | HSD11B1GAAHPGDALDH1A1ATM | |
| SCHEMBL4943340 | 0.74 | METAP1 (0.46) | HSD11B1MMP1MMP2GAAHPGD | |
| SCHEMBL7166438 | 0.74 | PPARD (0.41) | PPARDHSD11B1MMP1MMP2GAA | |
| SCHEMBL2326336 | 0.73 | PPARD (0.41) | PPARDMMP1MMP2FNTAFNTB | |
| SCHEMBL3928093 | 0.73 | PPARD (0.41) | PPARDFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1585729-A1 | 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063158-A1 | 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-07-29 | — | — | WO | disclosed |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | C3AR1, C1R, HRH4 | PPARD 2701/4885HSD11B1 542/4885MMP1 915/4885 |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | PTGER1, PTGER2, PTGER4 | PPARD 287/4885HSD11B1 1397/4885MMP1 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.